In patients, it is well-established that durable responses to immune checkpoint blockade (ICB) are associated with IFNγ-related gene signatures12, which are also correlated with increased tumour mutational burden (TMB)13 and T cell infiltration14, suggesting that IFNγ-driven responses is a pre-requisite to ICB response. This evidence concerns the gene IFNG and neoplasm.